Cite
Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
MLA
Lebrun, Christine, et al. “Therapeutic Target of Memory B Cells Depletion Helps to Tailor Administration Frequency of Rituximab in Myasthenia Gravis.” Journal of Neuroimmunology, vol. 298, Sept. 2016, pp. 79–81. EBSCOhost, https://doi.org/10.1016/j.jneuroim.2016.07.009.
APA
Lebrun, C., Bourg, V., Bresch, S., Cohen, M., Rosenthal-Allieri, M. A., Desnuelle, C., & Ticchioni, M. (2016). Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. Journal of Neuroimmunology, 298, 79–81. https://doi.org/10.1016/j.jneuroim.2016.07.009
Chicago
Lebrun, Christine, Véronique Bourg, Saskia Bresch, Mikael Cohen, Maria Alessandra Rosenthal-Allieri, Claude Desnuelle, and Michel Ticchioni. 2016. “Therapeutic Target of Memory B Cells Depletion Helps to Tailor Administration Frequency of Rituximab in Myasthenia Gravis.” Journal of Neuroimmunology 298 (September): 79–81. doi:10.1016/j.jneuroim.2016.07.009.